Although CAR T-cells directed toward the HER2-expressing tumors have been extensively studied in clinical trials, safety concerns have emerged following the death of a CRC patient who received 1×1010 third-generation HER2-CAR T-cells (61). This evidence concerns the gene ERBB2 and colorectal carcinoma.